Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2025 value amounting to $668000.0.

  • Gyre Therapeutics' Capital Expenditures fell 360.75% to $668000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $981000.0, marking a year-over-year decrease of 7914.54%. This contributed to the annual value of $2.3 million for FY2024, which is 7281.91% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Capital Expenditures of $668000.0 as of Q3 2025, which was down 360.75% from $256000.0 recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Capital Expenditures peaked at $2.5 million during Q2 2023, and registered a low of -$65000.0 during Q4 2024.
  • Moreover, its 4-year median value for Capital Expenditures was $680500.0 (2024), whereas its average is $1.0 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Capital Expenditures soared by 15230.77% in 2021, and later tumbled by 10279.69% in 2024.
  • Quarter analysis of 4 years shows Gyre Therapeutics' Capital Expenditures stood at $492000.0 in 2021, then soared by 372.36% to $2.3 million in 2023, then plummeted by 102.8% to -$65000.0 in 2024, then skyrocketed by 1127.69% to $668000.0 in 2025.
  • Its Capital Expenditures stands at $668000.0 for Q3 2025, versus $256000.0 for Q2 2025 and $122000.0 for Q1 2025.